|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Center for Medical Genetics and Molecular Medicine (T.F., P.K., H.B.) and Department of Neurology (L.A.B.), Haukeland University Hospital, Bergen; Department of Clinical Medicine (P.K., H.B., L.A.B.), University of Bergen, Norway; Department of Human Genetics (J.M.), McGill University and Genome Québec Innovation Centre (J.M.), Montreal, Québec, Canada; and Department of Pediatrics and Clinical Chemistry, Laboratory of Genetic Metabolic Diseases (R.J.W.), Academic Medical Center, University of Amsterdam, The Netherlands.
Address correspondence and reprint requests to Professor Laurence Bindoff, Department of Neurology, Haukeland University Hospital, N-5021 Bergen, Norway laurence.bindoff{at}helse-bergen.no
Objective: Clinical and genetic characterization of a neurologic disorder resembling Refsum disease in a Norwegian consanguineous family.
Methods: The affected individuals comprise a brother and sister and their third cousin. The family comes from a small island community and genealogic studies showed that both sets of parents are descendants of a man born in 1585. Based on the hypothesis that this is an autosomal recessive disease and that the patients were homozygous for the same mutation (identical by descent), we used homozygosity mapping to define the genetic locus of this disorder.
Results: This slowly progressive disorder starts in childhood with signs of peripheral neuropathy (pes cavus, tendoachilles contracture). Hearing loss and cataract become evident in the third decade. Subsequently, patients develop a disorder of gait due to the combination of ataxia and spasticity, and a pigment retinopathy. While the clinical picture is reminiscent of Refsum disease, affected individuals have normal phytanic and pristanic acid levels in plasma, as well as normal enzymatic activity for
-oxidation. We mapped the disease to a 15.96 Mb region on chromosome 20 (20p11.21-q12), containing approximately 200 genes (maximum lod score = 6.3). Sequencing of 23 candidate genes failed to demonstrate detrimental sequence variants.
Conclusions: Our findings show that the clinical syndromes that include Refsum disease are more heterogeneous than previously recognized. We have chosen to report the clinical features and mapping of this novel disorder in the hope that this will permit identification of other families and thus proper genetic characterization.
Abbreviations: HMSN = hereditary motor and sensory neuropathy; IBD = identical by descent; NARP = neuropathy, ataxia, and retinitis pigmentosa; SCA7 = spinocerebellar ataxia type 7.
e-Pub ahead of print on November 12, 2008, at www.neurology.org.
Supported by Helse Vest (Western Norway Regional Health Authority) (911308 to P.K., T.F., H.B.).
Disclosure: The authors report no disclosures.
Received February 6, 2008. Accepted in final form June 12, 2008.
Related Article
Neurology 2009 72: 13.
This article has been cited by other articles:
![]() |
T. D. Bird A new disease mimicking Refsum syndrome Neurology, January 6, 2009; 72(1): 13 - 13. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |